Imugene is passionate about bringing effective new treatments and options to patients who need them.

Participation in Imugene clinical trials is always based on the patient’s own decision. For further information on how to participate in our clinical trials, please contact your treating physician.

 

VAXINIA (CF33 + hNIS)

MAST: Open Label, Adaptive Phase 1 Study in Mixed Advanced Solid Tumours

NOW RECRUITING IN AUSTRALIA & USA

CHECKvacc (CF33 + hNIS + PD-L1)

Open Label, Phase 1 Investigator Sponsored Study in Triple Negative Breast Cancer

NOW RECRUITING IN THE USA

 

PD1-Vaxx (PD-1)

IMPRINTER: Open Label, Phase 1 Study of PD1-Vaxx in Adults with Non-Small Cell Lung Cancer

Now recruiting in Australia & USA

HER-Vaxx (HER-2)

nextHERIZON: Open Label, Phase 2 Study of HER-Vaxx in combination with chemotherapy or pembrolizumab in metastatic gastric cancer after progression on trastuzumab

NOW RECRUITING IN AUSTRALIA AND TAIWAN

* arm assignment based on previous PD-1/PD-L1 treatment

HERIZON: Open Label, Phase 1b/2 study of HER-Vaxx and Chemotherapy compared to Chemotherapy only in patients with HER-2 positive advanced Gastric Cancer.

B-Vaxx